EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Targeting immune checkpoints on myeloid cells: current status and future directions

Chuhan Ma, Yang Li, Min Li, Chao Lv, Yu Tian

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-024-03856-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Chuhan Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shengjing Hospital of China Medical University, ShenyangLiaoning Province, 110004, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Immune Checkpoint Proteins, Myeloid Cells, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Shengjing Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloid cells accumulate extensively in most tumors and play a critical role in immunosuppression of the tumor microenvironment (TME). Like T cells, myeloid cells also express immune checkpoint molecules, which induce the immunosuppressive phenotype of these cells. In this review, we summarize the tumor-promoting function and immune checkpoint expression of four types of myeloid cells: macrophages, neutrophils, dendritic cells, and myeloid-derived suppressor cells, which are the main components of the TME. By summarizing the research status of myeloid checkpoints, we propose that blocking immune checkpoints on myeloid cells might be an effective strategy to reverse the immunosuppressive status of the TME. Moreover, combining nanotechnology, cellular therapy, and bispecific antibodies to achieve precise targeting of myeloid immune checkpoints can help to avoid the adverse effects of systemic administration, ultimately achieving a balance between efficacy and safety in cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsImmune Checkpoint ProteinsMyeloid CellsNeoplasmsTumor MicroenvironmentAnimalsHumansImmunotherapy

Stichwörter der Autor:innen

Immune checkpointMyeloid cellsNanotherapyTumor microenvironment

Substanzen

Immune Checkpoint InhibitorsImmune Checkpoint Proteins

Autor:innen und Institutionen

  • Department of General Surgery, Shengjing Hospital of China Medical University, ShenyangLiaoning Province, 110004, China.
  • Department of Mammary Gland, Dalian Women and Children's Medical Center (Group), DalianLiaoning Province, 116000, China.
  • Department of General Surgery, Shengjing Hospital of China Medical University, ShenyangLiaoning Province, 110004, China. clu@cmu.edu.cn.
  • Department of General Surgery, Shengjing Hospital of China Medical University, ShenyangLiaoning Province, 110004, China. yu.tian@cmu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Shengjing Hospital

Zitieren

APA

Ma, C., Li, Y., Li, M., Lv, C., & Tian, Y. (2025). Targeting immune checkpoints on myeloid cells: current status and future directions. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03856-6

Vancouver

Ma C, Li Y, Li M, Lv C, Tian Y. Targeting immune checkpoints on myeloid cells: current status and future directions. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03856-6

BibTeX
@article{Ma2025,
  author = {Ma, Chuhan and Li, Yang and Li, Min and Lv, Chao and Tian, Yu},
  title = {Targeting immune checkpoints on myeloid cells: current status and future directions},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-024-03856-6}
}
Kostenlos starten →